Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Feasibility Study of Blood Biomarker Identification in Cervical Cancer (CLARITY)

31 de agosto de 2026 atualizado por: Queensland Centre for Gynaecological Cancer

Feasibility Study of Blood Biomarker Identification in Cervical Cancer: Performance of Cell-free DNA Versus Extracellular Vesicles

This study aims to explore whether a simple blood test can be used to help detect and monitor cervical cancer. The investigators are studying tiny fragments and particles found in blood, called cell-free DNA (cfDNA) and extracellular vesicles (EVs), to determine whether these can act as early warning signs (biomarkers) of cervical cancer.

Cell-free DNA (cfDNA) refers to tiny fragments of genetic material (DNA) that are naturally released from cells into the bloodstream when cells die or renew. Cell-free DNA circulates naturally in the blood. In people with cancer, some of the cfDNA originates from cancer cells; this component is called circulating tumour DNA (ctDNA). Analysis of cfDNA can detect signs of cancer, such as specific genetic changes or pieces of viral DNA, including human papillomavirus (HPV) DNA, without requiring removal of tissue from the cervix.

Extracellular vesicles (EVs) are very small "packages" released by cells into the blood and other body fluids. EVs carry messages between cells and contain important information such as proteins, fats, and genetic material, including RNA. In cancer, tumour cells release EVs that reflect tumour behaviour and activity. Analysis of EVs can provide information about cancer growth and response to treatment.

Together, cfDNA and EVs can act as tiny messengers or "fingerprints" of biological processes occurring inside the body. Analysis of cfDNA and EVs in blood samples may support the development of a simple, less invasive, more comfortable, and more accessible approach to detecting and monitoring cervical cancer compared with current screening and diagnostic methods. A blood test could also assist doctors in monitoring treatment response or detecting early signs of recurrence without requiring a surgical biopsy.

The expected outcomes of this study are to identify specific patterns or "signatures" in extracellular vesicles (EVs) and cell-free DNA (cfDNA) found in blood samples. These signatures could help to:

Detect cervical cancer earlier, before symptoms appear or the disease progresses.

Monitor treatment response in real time without the need for invasive tests. Predict whether cervical cancer might recur or spread after treatment. Support more personalised care by helping doctors select the most suitable treatment for each participant.

Visão geral do estudo

Descrição detalhada

This study is an open-label, prospective, experimental study of patients with cervical cancer. The primary aim is to evaluate the feasibility, clinical utility, and analytical performance of extracellular vesicles (EVs) and cell-free DNA (cfDNA) as minimally invasive, blood-based biomarkers for the early detection, treatment monitoring, and post-treatment surveillance of cervical cancer, with the potential to inform future screening and therapeutic strategies.

Cervical cancer continues to impose significant physical, emotional, and financial burdens on women worldwide. Despite advances in prevention and treatment, a critical need remains for more effective, non-invasive tools to support early detection, monitor treatment response, and guide clinical decision-making. As the field of cervical cancer diagnosis evolves, interest is growing in the use of blood-based biomarkers, particularly extracellular vesicles (EVs) and cell-free DNA (cfDNA), to improve patient care.

This study aims to evaluate the potential of EVs and cfDNA as minimally invasive biomarkers in the management of cervical cancer. Analysis of EVs and cfDNA is intended to provide deeper insights into the roles of these biomarkers in tumour development, progression, and intercellular communication. The anticipated outcomes include the identification of EV- and cfDNA-based signatures that can:

Facilitate earlier detection of cervical cancer. Enable real-time monitoring of treatment response. Predict recurrence and disease progression. Support the development of personalised therapeutic strategies.

By generating preliminary comparative data on the diagnostic accuracy of EVs and cfDNA, this study will provide a critical foundation for future large-scale investigations. The study is intended to contribute to the development of a novel, blood-based screening and monitoring tool that could enable earlier intervention and improve long-term outcomes.

A reliable, non-invasive test could also provide a more accessible and acceptable alternative to current cervical screening methods, particularly for women who face cultural, systemic, or personal barriers to participation. This is especially important for under-screened populations, including Aboriginal and Torres Strait Islander women and culturally diverse communities.

Ultimately, this research is expected to advance understanding of the biological role of EVs and cfDNA in cervical cancer pathogenesis and progression. The research supports the development of clinically effective, personalised diagnostic tools that may improve outcomes, reduce healthcare costs, contribute to Australia's national strategy to eliminate cervical cancer as a public health issue, and address persistent inequities in access to care.

Study Intervention

This prospective cohort study will enrol 100 patients with stage IA to IVB cervical cancer who are undergoing either primary surgical treatment, radiotherapy (RT), or chemoradiotherapy (CRT).

The study intervention involves the collection of approximately 40 mL of blood at baseline, following the initial diagnosis of cervical cancer, for the analysis of cell-free DNA, extracellular vesicles, and germline DNA. Additional blood samples of the same volume will be collected at two subsequent time points: at 8 weeks following surgery or completion of chemoradiotherapy (CRT), and at 6 months post-baseline.

In addition, quality-of-life questionnaires will be completed by participants at the following time points:

First time point: Baseline: For participants undergoing primary surgery, baseline is the date of surgery. For participants undergoing definitive radiotherapy or chemoradiotherapy, baseline is the date of the first radiation dose. Baseline assessments can be performed up to 30 days before the date of surgery or up to 30 days before the first radiation dose.

Second time point: Immediately after completion of radiotherapy or chemoradiotherapy (+14 days), or 8 weeks after surgery (±14 days).

Third time point: 6 months post-baseline (±14 days). Follow-up (24 Months)

Participant disease status will be recorded at 24 months (±30 days) through review of participants' medical records.

In accordance with current European Society for Medical Oncology (ESMO) guidelines, patients diagnosed with early-stage invasive cervical cancer, such as FIGO stage IA to IB2 and selected IIA1, typically undergo primary surgical treatment, including radical hysterectomy or simple hysterectomy. For these patients, the second blood collection will occur at 8 weeks post-surgery (±14 days).

For patients with locally advanced cervical cancer (LACC), for whom primary surgery is not recommended because of poor outcomes or increased morbidity associated with combined treatments, such as FIGO stages IB3, IIA2, IIB, and IIIA-IIIB, the preferred or definitive treatment is concurrent chemoradiotherapy (CRT) followed by internal radiation (brachytherapy). In these cases, the second blood sample will be collected at the end of treatment (+14 days).

Tipo de estudo

Observacional

Inscrição (Estimado)

100

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Queensland
      • Brisbane, Queensland, Austrália, 4029
        • Recrutamento
        • Royal Brisbane and Women's Hospital
        • Contato:
        • Contato:
        • Investigador principal:
          • Kristen Moloney

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Método de amostragem

Amostra Não Probabilística

População do estudo

100 patients with histologically confirmed squamous cell carcinoma or adenocarcinoma of the cervix (stage 1a to 4b).

Descrição

Inclusion Criteria:

  • Females, over 18 years, with histologically confirmed squamous cell carcinoma or adenocarcinoma of the cervix (stage 1a to 4b)
  • Undergo intensive primary surgical treatment, radiotherapy (RT) or chemoradiotherapy (CRT).
  • Signed written informed consent

Exclusion Criteria:

  • Unable to provide informed consent
  • Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator)
  • Prior malignancies <5 years before inclusion, except for successfully treated keratinocyte skin cancers, or ductal carcinoma in situ.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Patients with Cervical Cancer
Patients with FIGO stage IA-IVB cervical cancer undergoing standard-of-care primary surgery, radiotherapy, or chemoradiotherapy. Treatment is determined by the participant's treating clinical team and is not assigned by the study protocol. Participants will undergo serial blood collection for cfDNA and extracellular vesicle analyses, complete patient-reported outcome and quality-of-life questionnaires, and have disease status assessed through medical record review. Archival tumour tissue obtained during routine diagnostic biopsy or surgery will also be retrieved where available for translational analyses.
Approximately 40 mL of blood will be collected at baseline, approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy, and 6 months (±14 days) post-baseline. Blood samples will be processed for isolation and analysis of cell-free DNA (cfDNA), extracellular vesicles (EVs), and germline DNA.
Outros nomes:
  • Coleta de bioespécimes
  • Peripheral blood collection
Blood-derived cell-free DNA (cfDNA) and extracellular vesicles (EVs) will be isolated and characterised using prespecified laboratory methods. cfDNA will be quantified, quality assessed, and may undergo sequencing. EVs will be characterised using methods including nanoparticle tracking analysis, transmission electron microscopy, western blotting, proteomics, and miRNA sequencing. Biomarker profiles will be evaluated in relation to disease stage, treatment response, and disease outcomes.
Participants will complete patient-reported outcome and quality-of-life questionnaires at baseline, approximately 8 weeks after surgery or completion of radiotherapy/chemoradiotherapy, and 6 months post-baseline. Assessments include the FACT-Cx, EQ-5D-5L, and self-reported lower-extremity lymphoedema questionnaires.
Formalin-fixed paraffin-embedded (FFPE) tumour tissue obtained during routine diagnostic biopsy or surgery will be retrieved from pathology laboratories where available. No research-specific tumour biopsy or surgery will be performed. Tumour tissue may undergo DNA extraction and sequencing for comparison with blood-derived DNA and other prespecified translational analyses.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Proportion of participants with successful blood collection and analysable cfDNA and EVs
Prazo: Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
Percentage of enrolled participants for whom blood is successfully collected and both cell-free DNA (cfDNA) and extracellular vesicles (EVs) are successfully isolated and meet prespecified laboratory quality-control criteria for the planned downstream analyses. Feasibility will be assessed at each of the three scheduled blood-collection time points.
Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Proportion of eligible patients who consent to participate
Prazo: At study screening/enrolment.
Percentage of eligible patients with cervical cancer who provide informed consent and enrol in the study among all eligible patients approached for participation.
At study screening/enrolment.
Proportion of cfDNA samples meeting prespecified analytical quality criteria
Prazo: Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
Percentage of collected plasma samples from which cell-free DNA (cfDNA) is successfully extracted and meets prespecified quality-control criteria for downstream analysis. cfDNA will be quantified and quality assessed, including assessment of yield, integrity, and suitability for planned molecular analyses and/or sequencing.
Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
Proportion of extracellular vesicle samples meeting prespecified analytical quality criteria
Prazo: Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
Percentage of collected plasma/serum samples from which extracellular vesicles (EVs) are successfully isolated and meet prespecified quality-control criteria for downstream analysis. EV quantity and characteristics will be evaluated using methods including nanoparticle tracking analysis, transmission electron microscopy, and assessment of positive and negative EV markers by western blotting.
Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
Association between baseline cfDNA profiles and cervical cancer stage
Prazo: Baseline
Association between baseline cell-free DNA (cfDNA) characteristics and cervical cancer stage (FIGO stage IA-IVB). Prespecified cfDNA measures and/or molecular signatures obtained from plasma will be evaluated for differences across disease stages. Where applicable, tumour tissue and germline DNA sequencing data will be used as reference controls.
Baseline
Association between baseline extracellular vesicle profiles and cervical cancer stage
Prazo: Baseline
Association between baseline extracellular vesicle (EV) characteristics and cervical cancer stage (FIGO stage IA-IVB). Prespecified EV characteristics, including EV quantity and molecular cargo such as proteins and miRNAs, will be evaluated for differences across disease stages.
Baseline
Association between changes in cfDNA biomarkers and response to radiotherapy or chemoradiotherapy
Prazo: From baseline to the post-treatment assessment, within 14 days following completion of radiotherapy or chemoradiotherapy.
Association between changes in cell-free DNA (cfDNA) biomarkers from baseline to the post-treatment assessment and treatment response among participants receiving radiotherapy or chemoradiotherapy. Treatment response will be determined according to the prespecified clinical and/or radiological response criteria defined in the protocol or statistical analysis plan.
From baseline to the post-treatment assessment, within 14 days following completion of radiotherapy or chemoradiotherapy.
Association between changes in extracellular vesicle biomarkers and response to radiotherapy or chemoradiotherapy
Prazo: From baseline to the post-treatment assessment, within 14 days following completion of radiotherapy or chemoradiotherapy.
Association between changes in extracellular vesicle (EV) characteristics from baseline to the post-treatment assessment and treatment response among participants receiving radiotherapy or chemoradiotherapy. EV characteristics may include quantity and prespecified molecular profiles, including protein and miRNA profiles. Treatment response will be determined using the prespecified clinical and/or radiological response criteria.
From baseline to the post-treatment assessment, within 14 days following completion of radiotherapy or chemoradiotherapy.
Association between cfDNA and EV biomarkers and 24-month disease outcome
Prazo: From baseline through 24 months (±30 days).
Association of baseline and longitudinal cell-free DNA (cfDNA) and extracellular vesicle (EV) biomarker profiles with disease status at 24 months, including recurrence or disease progression as defined in the protocol. Disease status will be determined through review of participants' medical records.
From baseline through 24 months (±30 days).
Completion rate of patient-reported outcome and quality-of-life questionnaires
Prazo: Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.
Percentage of participants who complete the scheduled patient-reported outcome measure (PROM) and quality-of-life (QoL) questionnaires at each assessment time point. Questionnaires include the Functional Assessment of Cancer Therapy-Cervix (FACT-Cx), EQ-5D-5L, and lower-extremity lymphoedema questionnaires.
Baseline; approximately 8 weeks (±14 days) after surgery or within 14 days following completion of radiotherapy/chemoradiotherapy; and 6 months (±14 days) post-baseline.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

15 de setembro de 2026

Conclusão Primária (Estimado)

15 de setembro de 2030

Conclusão do estudo (Estimado)

15 de setembro de 2032

Datas de inscrição no estudo

Enviado pela primeira vez

27 de agosto de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

27 de agosto de 2026

Primeira postagem (Real)

1 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

2 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

31 de agosto de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

There is not a plan to make IPD available

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever